Dengue vaccine tetravalent(Takeda)(Dengue vaccine tetravalent(Takeda)) - 在研适应症：登革热_专利_临床

概要

基本信息

药物类型

减毒活疫苗、预防性疫苗、多价疫苗

别名

DEN1-DEN2-DEN3-DEN4 vaccine、Dengue vaccine tetravalent、DENVax

+ [6]

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

感染

在研适应症

登革热

非在研适应症-

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

Takeda Pharmaceutical Co., Ltd.Takeda Pharmaceuticals International AG

非在研机构-

权益机构

Biological E. Ltd.

Takeda Pharmaceutical Co., Ltd.

Inviragen, Inc.

最高研发阶段批准上市

首次获批日期

印尼 (2022-08-22),

登革热

最高研发阶段(中国)-

特殊审评优先审评 (美国)

登录后查看时间轴

关联

30

项与 Dengue vaccine tetravalent(Takeda) 相关的临床试验

NCT06579755

/ Not yet recruiting临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled (Older Adults, Aged >60 to 79 Years) and Open-Label (Adults, Aged 45 to 60 Years), Multicenter Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) Administered Subcutaneously to Adults and Older Adults With or Without Comorbidities in Endemic Areas for Dengue

Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. Researchers have seen that dengue fever now also happens more often in elderly persons. The main aim of this study is to learn more about the side effects of TDV in adult (45 - 60 years) and elderly (60 - 79 years) persons and about TDV's ability to create an immune response in adult and elderly persons. Another aim is to learn about the side effects of TDV in adult and elderly persons in endemic countries who have one or more additional medical conditions (called comorbidities) such as diabetes mellitus, hypertension or a chronic kidney condition.
In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first).
During the study, participants will visit their study clinic 5 times.

开始日期2026-04-01

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

NCT07047521

/ Recruiting临床3期

A Randomized, Double-Blind, Phase 3 Trial to Investigate the Immunogenicity and Safety of a New Formulation of Tetravalent Dengue Vaccine (TDV) Versus the Current Formulation of TDV in Healthy Adults (Aged 18-60 Years) in a Non-Endemic Area for Dengue

Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever. The TDV in current formulation has been approved by health authorities in many countries around the world. The main aim of the study is to confirm that the TDV new formulation induces the similar immune response as approved TDV.
Healthy adults who live in an area in which dengue fever does not occur will receive 2 TDV vaccinations 3-months apart with either the new or the current TDV. Blood samples will be taken before and after the vaccinations. These are necessary to check how well the vaccine works to activate the immune system. During the study, participants will visit their study clinic 5 times.

开始日期2025-11-07

申办/合作机构

Takeda Pharmaceutical Co., Ltd.

CTIS2025-520655-92-00

/ Recruiting临床4期IIT

An open non-randomized phase IV trial examining interfering cross-reactivity in serological diagnostics of flavivirus infections in Swedish travelers following vaccination with the live dengue vaccine Qdenga

开始日期2025-09-11

申办/合作机构-

100 项与 Dengue vaccine tetravalent(Takeda) 相关的临床结果

登录后查看更多信息

100 项与 Dengue vaccine tetravalent(Takeda) 相关的转化医学

登录后查看更多信息

100 项与 Dengue vaccine tetravalent(Takeda) 相关的专利（医药）

登录后查看更多信息

145

项与 Dengue vaccine tetravalent(Takeda) 相关的文献（医药）

2026-05-01·JOURNAL OF VIROLOGICAL METHODS

Animal models illuminate dengue immunopathogenesis to guide vaccine and therapeutic developments

Review

作者: Shabbir, Muhammad Nadir ; Linh, Duong Thuy

Dengue virus (DENV) infection affects over 390 million people annually, and its severe forms, including dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS), occur as a result of antibody-dependent enhancement (ADE), T-cell dysregulation, and a cytokine storm. This review integrates the results of human immunopathology with those reported by animal models, consolidating the findings in a systematic manner to validate these mechanisms. Research on AG129 interferon receptor-deficient mice consistently demonstrates ADE-mediated viremia and vascular leakage. However, humanized NSG-BLT mice recapitulate the classic antigenic sin of human T cells after heterotypic challenge with DENV. Cynomolgus macaque models are physiologically relevant for testing tetravalent vaccines under near-human circulatory conditions, and diet-induced obese mice are used to phenotype the effects of metabolic comorbidities on IL-1β-driven immunopathology. Data using standardized methods, including Evans blue extravasation assays, multiplex cytokine panels, and endpoints compliant with the ARRIVE 2.0 guidelines for animal research reporting, were associated with human clinical results. ARRIVE 2.0 is a set of guidelines to improve the transparency and reproducibility of animal research. It is worth noting that early experimental studies on the effectiveness and safety of Dengvaxia reported breakthrough viremia in macaque models. The protection provided by the monoclonal antibody C10 was shown to mitigate antibody-dependent enhancement (ADE) in murine models, though it is not associated with the Dengvaxia vaccine. The further development of these animal models will be necessary to expedite the safe development of next-generation dengue vaccines (TAK-003, TV003/TV005), antivirals (favipiravir, sofosbuvir), and immune modulators (IL-6 and TNF-α blockers) for use in endemic areas.

2026-02-01·BIOMEDICINE & PHARMACOTHERAPY

Preclinical evaluation of DENV1 mRNA vaccines in mice: Toward improved neutralizing antibody and T cell responses

Article

作者: Wangsoontorn, Pachara ; Puttikhunt, Chunya ; Kaewpang, Papatsara ; Heyes, James ; Pitakpolrat, Patrawadee ; Buranapraditkun, Supranee ; Weissman, Drew ; Tharakhet, Kittipan ; Prompetchara, Eakachai ; Lam, Kieu ; Ketloy, Chutitorn ; Ruxrungtham, Kiat ; Yostrerat, Nongnaphat ; Saithong, Supichcha ; Khawsang, Chirayus

Dengue virus (DENV) infection represents a significant public health concern in tropical and subtropical areas, with increasing cases in parts of Europe. Currently, licensed vaccines, Dengvaxia® and Qdenga®, rely on live-attenuated platforms but show limited efficacy due to imbalanced immune responses and risks associated with antibody-dependent enhancement (ADE). In this study, we developed and evaluated nucleoside-modified mRNA vaccine encoding the dengue virus serotype 1 (DENV1) pre-membrane and envelope (prME) proteins. To reduce the potential for ADE, we incorporated the F108A mutation in the fusion loop, substituted the pr region with that from Japanese encephalitis virus (JEV), and incorporated a consensus envelope domain III (cEDIII) sequence to broaden neutralizing antibody responses. Immunogenicity was assessed in BALB/C mice immunized twice at three-week intervals with 1, 2.5, or 10 μg doses. The WT prME construct induced the highest DENV1 neutralizing antibody (NtAb) titers in a dose-dependent manner and robust T cell responses, particularly with the 2.5 μg dose. While the F108A and cEDIII modifications modulated antigen expression and broadened cross-reactivity, they also slightly reduced DENV-1-specific neutralizing titers. Among constructs, F108A+cEDIII demonstrated reduced ADE activity with improved cross-neutralization, especially against DENV3. However, the prJEV chimera exhibited low immunogenicity, likely due to prM-E domain incompatibility. Overall, the WT prME construct showed the most favorable balance of immunogenicity and safety, supporting its advancement as a prototype for future tetravalent dengue mRNA vaccine development.

2026-01-01·LANCET INFECTIOUS DISEASES

Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study

Article

作者: Brumatti, Thiago Sanches ; Ko, Albert I ; D' Agostini, Tatiana Lang ; de Oliveira, Roberto Dias ; da Silva, Patricia Vieira ; Mareto, Lisany Krug ; Andrews, Jason R ; Hitchings, Matt D T ; Croda, Julio ; Lazar Neto, Felippe ; Cummings, Derek A T ; Dean, Natalie E ; Dos Santos, Edinéia Ribeiro ; Ranzani, Otavio T ; De Paula, Regiane A Cardoso

BACKGROUND:

Dengue is a substantial public health challenge in tropical regions, and is considered a global health threat owing to its expanding geographical range and increasing incidence as a result of climate change. Despite the availability of tetravalent dengue vaccines, real-world evidence on their effectiveness is scarce. We aimed to evaluate the vaccine effectiveness of the dengue vaccine TAK-003 in adolescents during the 2024 dengue outbreak in the state of São Paulo, Brazil.

METHODS:

This test-negative, case-control study was conducted among adolescents aged 10-14 years in São Paulo state, Brazil, from Feb 20 to Dec 31, 2024. Cases were defined as individuals with acute febrile illness and virologically confirmed dengue, and controls as individuals with acute febrile illness who tested negative for dengue; in both groups, confirmation was based on NS1 antigen or RT-PCR testing within 5 days of symptom onset. Data were obtained from the national surveillance databases for dengue and the São Paulo State Secretary of Health vaccination registry. We used mixed-effects logistic regression models to estimate vaccine effectiveness against symptomatic, virologically confirmed dengue and against hospitalisation with dengue after one or two doses of the vaccine.

FINDINGS:

Of 128 358 potentially eligible tests, 92 621 were included in the analysis: 43 873 from cases and 48 748 from controls. Adjusted vaccine effectiveness was 50·2% (95% CI 45·0-54·9) for the first dose and 61·7% (39·9-75·6) for the second dose against symptomatic dengue, and 67·5% (95% CI 43·4-81·3) for the first dose against hospitalisation with dengue. Protection against symptomatic disease began 14 days after the first dose (67·4% [57·2-75·1] at 14-27 days), but declined to 49·7% (30·4-63·6) after 90 days from the first dose. Sensitivity analyses showed the robustness of these findings, although estimates for the second dose were limited by the small number of events observed.

INTERPRETATION:

TAK-003 was effective against symptomatic dengue and hospitalisation with dengue in adolescents during a large outbreak caused predominantly by dengue virus serotypes 1 and 2. These findings underscore the importance of real-world evidence in guiding dengue vaccination strategies, particularly in high-transmission settings and during emergency response use.

FUNDING:

National Council for Scientific and Technological Development.

TRANSLATION:

For the Portuguese translation of the abstract see Supplementary Materials section.

118

项与 Dengue vaccine tetravalent(Takeda) 相关的新闻（医药）

2026-01-29

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1-2期（2026年1月29日更新）

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75 THE LANCET Infectious Diseases. Volume 26Number 2 柳叶刀传染病学 26卷 2期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Call for letters 征稿启事 The Lancet Infectious Diseases The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111 Comment（述评） 2 Long COVID is here to stay—even in children 长期新冠症状将持续存在——即使在儿童中亦是如此 Danilo Buonsenso The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112 3 Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment 利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用 Ming Hong Choi,Ivan Fan Ngai Hung The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113 4 A new monoclonal in the arMAMentarium against malaria 抗疟“武器库”中的新型单克隆抗体 Freia-Raphaella Lorenz,Matthew B B McCall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115 5 Household transmission of mpox in Africa: limited in adults but more prevalent in children 非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍 Oriol Mitjà,Michael Marks The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117 6 The lasting lessons of mpox: infection, vaccination, and immune memory 猴痘带来的持久教训：感染、疫苗接种和免疫记忆 Raianna Fantin,Camila H Coelho The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118 7 Xpert-Ultra for diagnosing asymptomatic tuberculosis Xpert-Ultra用于诊断无症状结核病 Xia Yu,Hairong Huang The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120 8 The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action 基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动 David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122 Correspondence（读者来信） 9 Spillover in dengue trials 登革热试验中的溢出效应 Thomas A Smith,Samuel I Watson The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77 10 Spillover in dengue trials – Author's reply 登革热试验中的溢出效应——作者回复 Fernando Abad-Franch The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78 11 Updating the traditional voriconazole trough concentration range 传统的伏立康唑谷浓度范围更新 Rongqiang Liao,Xiaoyuan Zheng The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79 12 Updating the traditional voriconazole trough concentration range – Authors' reply 传统的伏立康唑谷浓度范围更新——作者回复 Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80 13 Clinical course and neurological profile of Kyasanur Forest disease 基萨努尔森林病的临床病程和神经特征 Nitin Gupta,Tirlangi Praveen Kumar The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82 Corrections（更正） 14 Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7 对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 15 Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4 对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 Newsdesk（新闻台） 16 Promising early data for sorfequiline 索氟维林早期数据令人鼓舞 Ed Holt The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84 17 Highlights from ASTMH 2025 2025年美国热带医学与卫生学会年会亮点 Marco De Ambrogi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85 18 Brazil approves domestic single-shot dengue vaccine 巴西批准国产单剂登革热疫苗 Marcia Triunfol The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86 19 CDC cuts to childhood vaccine recommendations 美国疾控中心削减儿童疫苗接种建议 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87 20 WHO launches unified plan for coronaviruses 世界卫生组织启动冠状病毒统一计划 Talha Burki The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88 21 Infectious disease surveillance update 传染病监测更新 Cahal McQuillan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89 22 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90 Obituary（讣告） 23 Walter Dowdle 沃尔特·道德尔 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124 Profile（人物简介） 24 Katie Anders—improving global dengue control 凯蒂·安德斯——改善全球登革热防控 Tony Kirby The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125 Media Watch（媒体观察） Film（电影） 25 Eliminating Guinea worm 根除麦地那龙线虫 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126 Articles（论著） 26 Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study 奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127 27 Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial 口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验 William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139 28 Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial 头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验 David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148 29 Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验 single-blind, randomised, controlled, dose-ranging, phase 2 trial Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160 30 Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial 人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验 Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170 31 Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study 布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究 Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182 32 Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study 比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究 Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190 33 Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study 乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究 Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203 Review（综述） 34 Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge 侵袭性A组链球菌感染：从2022-23年激增中吸取的教训 Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91 35 A clinical practice guideline for tuberculous meningitis 结核性脑膜炎临床实践指南 Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96 36 Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults 缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症 Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112 Personal View（个人观点） 37 A transformation in cholera surveillance 霍乱监测的变革 Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124 Clinical Picture（临床图像） 38 Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing 尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展 Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130

疫苗信使RNA临床研究临床1期

2026-01-25

·药时空

无需冷链的稳定型登革热疫苗要来了？

摘要：登革热，这个听起来有点遥远的名字，其实正以前所未有的速度席卷全球，热带、亚热带地区的人们更是深受其扰。传统的疫苗策略，比如减活疫苗，虽然有用，但总有些让人头疼的“副作用”，比如可能引发更严重的疾病。今天，咱们就来聊聊一种被称为 “病毒样颗粒” 的新一代疫苗技术，它就像给病毒做了一个逼真的“蜡像”，有模有样，但绝对安全。这篇文章将带你看看，科学家们如何用这种“空壳”技术，试图攻克登革热疫苗的百年难题，从实验室的瓶瓶罐罐，一路谈到如何让它真正走进千家万户。一、登革热：一个不断升级的全球威胁不知道你发现没有，这几年关于登革热的新闻越来越多了。这可不是错觉，登革热的全球发病率在过去二十年里增长了八倍多。想想看，全球约一半人口都生活在登革热流行区，这个数字本身就挺吓人的。光是2023年，全球就报告了超过650万病例和约6800例死亡，创下历史纪录。问题出在哪？快速的城市化、气候变化，还有那杀之不尽的蚊子，都让疫情控制变得异常艰难。更麻烦的是，目前还没有特效的抗病毒药物，于是，研发有效的疫苗就成了我们手中最关键的武器之一。但这条路，走得并不顺畅。二、传统疫苗的“阿喀琉斯之踵”：ADE效应登革热病毒有四个不同的血清型，感染一种获得的免疫力，对其它几种保护力很弱，甚至可能帮倒忙。这个“帮倒忙”的机制，就是大名鼎鼎的抗体依赖性增强效应。简单来说，如果你之前感染过一种登革热，体内产生了抗体，但水平不高。当你再感染另一种血清型时，这些“半吊子”抗体会结合新病毒，非但不能消灭它，反而像给它开了张VIP通行证，护送它更容易进入免疫细胞，导致病毒大量复制，病情反而更重。下图就清晰地展示了这个“引狼入室”的过程。图1：ADE机制示意图第一支获批的登革热疫苗Dengvaxia就曾因此陷入争议。它对不同血清型的保护效果不均，尤其在未感染过登革热的人群中，反而增加了住院风险。这给整个疫苗研发领域敲响了警钟：安全，必须是第一位的。三、 VLP疫苗：安全的“模仿者” 正是在这种背景下，病毒样颗粒技术走进了科学家的视野。你可以把它想象成病毒的“高仿模型”。它由病毒的外壳结构蛋白自我组装而成，形态、表面抗原和真病毒几乎一模一样，但最关键的是——它没有病毒的遗传物质内核，因此不会复制、不会致病。图2：病毒颗粒与VLP结构对比示意图这种“空壳”设计带来了巨大优势。首先，安全性极高，特别适合儿童和免疫力低下的人群。其次，它能精准地展示病毒表面的关键蛋白，诱导机体产生强效的中和抗体。更有意思的是，科学家还能对VLP进行“精装修”，比如特意去掉那个容易引发ADE的prM蛋白，从而让免疫反应更“纯净”，更偏向于产生保护性抗体，从源头上降低风险。四、如何大规模制造“病毒空壳”？理想很丰满，但要把VLPs从实验室的珍品变成能打上亿支的疫苗，还得解决量产问题。这涉及到选择什么样的“工厂”来生产这些颗粒。不同的表达系统各有千秋，就像不同的生产线，在成本、产量和产品“保真度”上需要权衡。比如，哺乳动物细胞（如CHO细胞）生产线，产品“仿”得最像，糖基化修饰几乎和人一样，但成本高、产量相对较低。昆虫细胞平台速度快、成本适中，是当前常用的折中方案，不过其糖基化模式和人略有不同。而酵母和植物表达系统则被寄予厚望，它们成本极低、易于大规模培养，尤其适合在资源有限的地区建立生产中心，虽然目前在产量和糖基化精确度上还需要进一步优化。五、让疫苗“扛得住”热带气候造出来还不够，还得能“活”着运到需要的人手里。登革热流行的地区多是热带，高温高湿，对疫苗的稳定性是巨大考验。有包膜的VLPs比无包膜的（如HPV疫苗）更娇贵，热了、晃了都可能让结构变形。图3：VLP疫苗稳定性策略示意图所以，制剂科学家们想了不少办法。比如添加蔗糖、海藻糖这类“防冻剂”，在冻干过程中保护VLP结构；加入微量的表面活性剂防止颗粒聚集；或者使用铝佐剂，既能增强免疫效果，也能像“支架”一样稳定抗原。最终目标，是开发出能耐受一定温度波动的冻干制剂，哪怕冷链条件不完善，疫苗也能保持效力。六、横向对比：VLP的竞争力如何？那么，VLP疫苗和目前其他技术路线的疫苗比起来，到底处在什么位置？减毒活疫苗（如TAK-003）免疫力持久，但存在潜在的ADE风险，且保护力对不同血清型可能不均。mRNA疫苗能激起非常高的抗体滴度，但超低温储存是个现实难题。DNA疫苗则擅长激发T细胞免疫，但产生抗体的能力较弱。相比之下，VLP疫苗似乎找到了一个不错的平衡点：它能诱导出平衡且强效的中和抗体反应，覆盖所有四个血清型；安全性好；生产工艺也相对成熟。在动物实验中，四价登革热VLP疫苗能让所有免疫的灵长类动物产生持续至少一年的保护性抗体，且没有观察到ADE。七、未来之路：从实验室到真实世界前景固然光明，但想把VLP疫苗成功推向市场，还有几道坎要过。首先是规模化生产的稳定性和成本，特别是在酵母和植物平台，需要继续提升产量。其次，临床试验必须足够严谨，尤其是在不同年龄、不同免疫背景的人群中，充分验证其安全性和持久的保护效果。我认为，一个特别有前景的策略是发展区域化制造中心，在登革热流行的东南亚、拉美等地建立本地化生产线，不仅能缩短供应链、降低成本，还能更快地应对疫情爆发，增强社区信任。同时，监管机构也需要更灵活的审批框架，比如探索用可靠的免疫保护相关性指标来加速评估过程。八、结语说到底，病毒样颗粒代表了一种更精巧、更可控的疫苗设计哲学。它放弃了用“活病毒”练兵的风险，转而用高度仿真的“空壳”来训练我们的免疫系统。对于登革热这种具有ADE特殊风险的疾病，这种思路显得尤为可贵。当然，科学没有银弹，VLP疫苗最终能否成为登革热的终结者，还需要更多临床数据的检验。但毫无疑问，它为我们提供了一条充满希望的新路径。从乙肝疫苗、HPV疫苗的成功，我们看到了VLP平台的实力。也许在不久的将来，我们也能拥有一支安全、高效、易于普及的登革热VLP疫苗，让热带地区的居民，能更安心地享受阳光与生活。识别微信二维码，可添加药时空小编请注明：姓名+研究方向！

疫苗

2025-12-28

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1期

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75

疫苗临床1期信使RNA

100 项与 Dengue vaccine tetravalent(Takeda) 相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
登革热	印尼	Takeda Pharmaceutical Co., Ltd.	2022-08-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06837116 (CTgov)	早期临床1期	登革热	29	Vaccine (SC ID)	壓糧構膚夢願糧糧壓夢(餘糧鹽選鏇積憲繭淵構) = 齋衊鹽糧觸齋製範窪遞夢衊鹹顧鹹範餘餘繭鑰 (鏇憲餘齋廠構鬱鹹顧鹹, 齋齋鬱選衊遞選窪衊顧 ~ 遞蓋構夢鑰壓醖襯糧網) 更多	-	2026-01-16
				Vaccine (SC SC)	壓糧構膚夢願糧糧壓夢(餘糧鹽選鏇積憲繭淵構) = 艱願醖窪膚範獵選蓋艱夢衊鹹顧鹹範餘餘繭鑰 (鏇憲餘齋廠構鬱鹹顧鹹, 鏇選窪糧壓鹹壓壓廠糧 ~ 鬱製簾淵壓鹹憲構襯構) 更多
NCT03341637 \| NCT02193087 \| NCT02948829 \| NCT03342898 \| NCT01511250 \| NCT04313244 \| NCT03999996 \| NCT03771963 \| NCT02302066 \| NCT02747927 \| NCT02425098 \| NCT03423173 \| NCT03746015 (TAK-003, Pubmed \| Expert Rev Vaccines)	临床2/3期	怀孕	557	TAK-003	夢醖蓋簾觸窪糧鑰廠醖(願鬱顧餘繭醖鏇鹹鑰淵) = 觸夢糧簾願壓夢築醖繭願觸鹹鏇廠積壓醖膚醖 (鹹糧鹽積構選壓築廠淵 ) 更多	积极	2025-12-31
				TAK-003 (Placebo)	夢醖蓋簾觸窪糧鑰廠醖(願鬱顧餘繭醖鏇鹹鑰淵) = 蓋鑰壓憲簾鏇餘獵鏇顧願觸鹹鏇廠積壓醖膚醖 (鹹糧鹽積構選壓築廠淵 ) 更多
NCT03999996 (CTgov)	临床3期	登革热	365	Dengue Tetravalent Vaccine+Live, Attenuated+Takeda (Prior to Booster: DEN-304)	簾壓築蓋網顧獵夢憲鹹(廠淵蓋鑰選鏇衊餘鹽顧) = 鏇夢觸繭窪糧鑰簾鏇襯製獵製觸積艱鹽襯蓋膚 (夢製遞壓觸襯廠醖構製, 選範遞遞憲遞網願選築 ~ 醖簾獵鏇艱範夢鹽餘選) 更多	-	2025-06-12
				Dengue Tetravalent Vaccine+Live, Attenuated+Takeda (Prior to Booster: DEN-315)	簾壓築蓋網顧獵夢憲鹹(廠淵蓋鑰選鏇衊餘鹽顧) = 壓淵襯齋齋壓蓋鹹窪範製獵製觸積艱鹽襯蓋膚 (夢製遞壓觸襯廠醖構製, 網簾襯廠構夢構餘觸糧 ~ 淵繭膚簾簾鑰夢鏇鑰製) 更多
NCT02747927 (DEN-301, Pubmed \| Clin Infect Dis)	临床3期	登革热	-	TAK-003 Vaccine	糧選廠鏇糧糧鏇壓鬱蓋(廠艱廠觸蓋艱衊壓構遞) = GMTs remained elevated against all 4 serotypes for ∼4 years postvaccination, with no evident differences across age groups 夢襯餘鬱襯鑰觸鹹繭壓 (獵築膚廠餘鹽醖構選願 )	积极	2025-02-05
NCT02747927 (Pubmed \| J Infect Dis)	临床3期	登革热 yellow fever vaccination	-	TAK-003	糧鬱製選顧範糧齋壓願(膚齋蓋積鏇簾遞夢簾鬱) = Within 28 days of any vaccination, the proportions of participants with serious adverse events in the YF/JE prior vaccination population were comparable between the TAK-003 and placebo groups 壓壓憲積範廠網範糧淵 (衊廠選醖艱膚願簾襯製 )	-	2024-12-16
NCT04313244 (CTgov)	临床3期	登革热	614	9vHPV Vaccine+Dengue Tetravalent Vaccine (TDV) (9vHPV+TDV)	選積壓襯襯簾廠齋壓壓(觸壓獵鹹願鏇鏇選鬱遞) = 鏇衊獵鹽鹹壓遞構餘艱餘衊鹽淵繭膚窪壓鑰廠 (餘選構築網顧鬱壓選窪, 網獵積獵顧簾鏇衊繭壓 ~ 衊窪觸網網網鏇齋願網) 更多	-	2024-02-07
				9vHPV Vaccine (9vHPV)	選積壓襯襯簾廠齋壓壓(觸壓獵鹹願鏇鏇選鬱遞) = 衊衊窪範淵衊製簾艱獵餘衊鹽淵繭膚窪壓鑰廠 (餘選構築網顧鬱壓選窪, 選製鹹襯繭餘顧鬱窪積 ~ 網鬱簾製艱遞鑰鏇遞積) 更多
NCT03342898 (Pubmed)	临床3期	登革热 \| 黄热病	900	YF-17D+TAK-003	齋壓鹽壓憲襯鏇築鑰製(鹽齋積艱築獵網餘衊觸) = 夢獵鏇繭簾鑰網鏇製襯醖糧窪選淵壓鹽積鑰範 (觸蓋製衊糧齋鹹襯蓋鑰 )	-	2023-03-01
NCT03525119 (Pubmed)	临床3期	登革热	900	HAV vaccine	遞製鹽艱遞醖壓餘憲蓋(餘築餘繭醖顧窪觸壓構) = 壓窪鬱範鹹鏇鏇顧餘繭築顧觸簾廠選糧淵鹽觸 (觸廠鹽鑰齋醖範窪憲襯 ) 更多	-	2023-01-19
				TAK-003	繭鑰糧構遞願鑰網網獵(鏇簾範膚淵齋淵願網構) = 夢顧範齋獵構餘廠鏇鏇鏇網夢積範鬱廠鑰鹽淵 (糧遞鹽鹹齋蓋齋顧鑰簾 )
NCT03771963 (TAK-003, CTgov)	临床3期	登革热	200	Tetravalent Dengue Vaccine (TDV)	願襯選構網選醖膚觸餘(遞簾齋鹽積齋網膚窪範) = 夢獵艱餘構襯顧壓窪艱壓衊鑰壓獵願簾顧觸獵 (壓襯窪遞膚襯網鬱網鏇, 餘鏇顧鹹蓋壓構願壓廠 ~ 壓繭築簾觸願簾淵觸觸) 更多	-	2021-06-07
NCT03341637 (Pubmed \| Rev Panam Salud Publica)	临床3期	-	400	TAK-003	顧憲壓淵選鹽衊遞窪餘(範鏇鏇憲願夢鹽壓鏇簾) = One MAAE in each group was considered treatment-related (TAK-003: injection-site erythema, and placebo: pharyngitis) 醖觸夢壓簾鏇廠鹹網網 (膚獵糧鑰廠鬱淵鹽製顧 )	-	2021-01-01
				Placebo